Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractile force in vitro and in vivo with an IC50 of 1.4 μM.
Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractile force in vitro and in vivo with an IC50 of 1.4 μM.
Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractile force in vitro and in vivo with an IC50 of 1.4 μM.
Afizagabar (S44819) is a first-in-class, competitive and selective α5-GABAAR antagonist with an IC50 value of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2.
Afizagabar (S44819) is a first-in-class, competitive and selective α5-GABAAR antagonist with an IC50 value of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2.
Aflatoxin B1 (AFB1) is a secondary metabolite of Aspergillus flavus and A. parasiticus. Aflatoxin B1 (AFB1) mainly induces the transversion of G-->T in the third position of codon 249 of the p53 tumor suppressor gene, resulting in mutation.
Aflatoxin B1 (AFB1) is a secondary metabolite of Aspergillus flavus and A. parasiticus. Aflatoxin B1 (AFB1) mainly induces the transversion of G-->T in the third position of codon 249 of the p53 tumor suppressor gene, resulting in mutation.
Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.
Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.